Ferring Innovation Grants
The 2019 Grant program will open May 13th!
Welcome to the Ferring Innovation Grants Portal from Ferring Research Institute.
- At Ferring we believe in the power of research to identify important new therapeutics.
- We are passionate about science and committed to exploring new directions.
- We believe in the value of partnership and working together to move science forward.
- We actively seek discoveries and innovation from internal and external sources.
Ferring is committed to building a portfolio of novel, innovative drugs to address indications of high unmet medical need for patients in our core therapeutic areas.
The Ferring Innovation Grants are awarded annually in January and are not renewable.
We will NOT fund clinical studies, or studies which require the collection of human samples under the direction of an Institutional Review Board.
If your proposal includes analysis of anonymized human samples, they must be collected independently of this application.
Please direct clinical research grant applications to Ferring USA educational grant program. https://ferring.envisionpharma.com/vt_ferring/
Ferring Innovation Grants Program Summary
We welcome you to share our brochure!
Ferring announces the recipients of the Ferring Research Institute Innovation Grants Program for 2018:
- Fiona Cousins, PhD – Hudson Institute of Medical Research, Monash University
New treatment of endometriosis in a preclinical model
- Laurent Derré, PhD – University Hospital of Lausanne (CHUV)
Immunotherapeutic strategies targeting ILC2 and MDSCs to treat bladder cancer
- Marta Dueñas, PhD – Fundación para la Investigación Hospital 12 de Octubre
Evaluation of miRNAs and miRNA derived peptides (miPEPs) in liquid biopsies for bladder cancer diagnosis, prognosis and BCG treatment response
- Tracey Edgell, PhD – Hudson Institute of Medical Research, Monash University
A novel non-hormonal therapeutic path for improving pregnancy success rates
- Pradipta Ghosh, MD – University of California, San Diego
Boolean Algorithms to Develop Precision Macrophage Reprogramming Therapeutics in IBD: From Math to (Wo)Man
- Emmet Hirsch, MD – NorthShore University HealthSystem
Surfactant Protein A (SP-A): A novel agent to prevent preterm birth.
- Harmeet Malhi, MD, BS – Mayo Clinic
Hepatocyte-derived extracellular vesicle sphingolipidomics are a diagnostic and prognostic biomarker in nonalcoholic steatohepatitis
- Hiroshi Miyamoto, MD, PhD – University of Rochester
The role of latrophilins in urothelial tumorigenesis: a novel chemopreventive target for bladder cancer